secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001104659-23-124182
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%
--------------------------------------------------------------------------

- Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.
- John Cavan (CFO) appointed interim CEO; Dr. Peter Wijngaard also resigns from board.
- Board approves strategic restructuring to reduce operating costs by ~60%, with one-time charge of $400-$800K in Q4 2023.
- Company to explore strategic alternatives including M&A, licensing, or sale; 131 patients in Phase 2b NASH trial.
- Cash runway extended into Q2 2025; will add trial patients only if fully funded or strategic deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/0001104659-23-124182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/tm2332355d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer